Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Phase 1 data for pruritus treatment
August 2017
SHARING OPTIONS:

STAMFORD, Conn.—Biopharmaceutical company Cara Therapeutics Inc. has reported summary results from its Phase 1 trial of Oral CR845 in chronic kidney disease patients undergoing hemodialysis. CR845 is being advanced as a treatment for moderate-to-severe pruritus in CKD patients undergoing hemodialysis. At present, there are no approved therapies for CKD-associated pruritus, a systemic itching condition seen most frequently in CKD patients receiving hemodialysis and peritoneal dialysis. The trial showed that all four tablet strengths—0.25, 0.5, 1.0 and 2.5 mg—were generally well tolerated when administered daily or after dialysis three times a week. Plasma levels from oral administration were comparable to or exceeded those seen with clinically efficacious IV doses of CR845. The frequency of treatment emergent adverse events (TEAEs) from CR845 treatment was similar to that seen in the placebo group, and TEAEs were generally mild.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.